pharmaphorum

OCTOBER 13, 2022

Top-line results from phase ALPINE pitted the two drugs against each other in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), and showed that Brukinsa (zanubrutinib) achieved better progression-free survival (PFS) compared to Imbruvica (ibrutinib), which made $10 billion in sales last year.

Side effects 52

Side effects Sales Marketing Competition 52

Pharmaceutical Technology

APRIL 24, 2023

The combination therapy also caused fewer side effects, with heart problems and hypertension as the most common ones, based on the final draft guidance. While Imbruvica maintained a previously strong position on the market, competition has chipped away at the inhibitor’s market share. While Imbruvica sales were $3.78

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

pharmaphorum

DECEMBER 12, 2022

Adverse events such as bruising, headaches, and blood in urine occurred at roughly the same frequency in both groups of patients in ADVANCE IV, and while serious side effects were seen in 8% of the Vyvgart group, that was lower than the 16% reported with placebo.

Side effects 52

Side effects Sales Competition Patients 52

pharmaphorum

JULY 11, 2022

One issue dogging the programmes has been cases of blood clots in late-stage trials, which prompted the FDA to place the drug under a clinical hold a few years ago. Sanofi acquired the drug when it bought Bioverativ in 2018 for $11.6 The post Sanofi trumpets data with haemophilia treatment duo at ISTH appeared first on.

Engineering 52

Engineering Side effects Competition Sales 52

Silver Line CRM

NOVEMBER 11, 2020

But today, the need to satisfy patients, providers, payers, regulatory agencies, and shareholders alike — while staying ahead of the competition — takes the right technologies at the right time. . But as we move forward into the next decade, they’ve gone from “nice to have” options to requirements to stay competitive.

Marketing 52

Marketing Pharmaceutical Side effects Insurance 52

pharmaphorum

DECEMBER 15, 2022

Back in 2015, the influencer-of-influencers, Kim Kardashian, was slammed for failing to mention the potential side effects of an anti-nausea drug, leading to the US FDA getting involved. Despite the slap on the wrist, the campaign was highly effective and there is no sign of this approach going away.

Media 80

Media Healthcare Healthcare Education 80

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. million in Q3.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. million in Q3.

Medical 98

Medical Manufacturing Insurance Side effects 98